Clinical Report: Persistent Inflammation in Cerebrospinal Fluid Following Natalizumab

Overview

This study investigates the persistence of intrathecal inflammation in patients with relapsing-remitting multiple sclerosis (RRMS) after long-term treatment with natalizumab (NTZ). It finds that certain biomarkers remain elevated in patients treated for over five years, particularly in those with positive oligoclonal bands (OCBs), indicating incomplete suppression of adaptive immune activation.

Background

Natalizumab is a high-efficacy therapy for RRMS that prevents immune cell migration into the central nervous system, thereby reducing inflammation. Understanding the long-term effects of NTZ on cerebrospinal fluid (CSF) biomarkers is crucial, as residual inflammation may contribute to ongoing disease activity and neurological decline. This study addresses the gap in knowledge regarding CSF inflammation after extended NTZ treatment durations.

Data Highlights

Key Findings

• Most CSF biomarkers were significantly lower in NTZ-treated patients compared to untreated RRMS patients.
• Elevated levels of sBCMA, sCD27, CHIT1, IgG index, and IL-10 were observed in NTZ-treated patients compared to controls.
• NTZ treatment duration inversely correlated with sCD27 levels.
• OCB-positive patients had higher levels of sCD27 and IgG index compared to controls after more than five years of NTZ treatment.
• Residual intrathecal inflammation persists in OCB-positive patients despite long-term NTZ therapy.

Clinical Implications

Clinicians should be aware that while NTZ effectively reduces CSF inflammation, some biomarkers may remain elevated, particularly in OCB-positive patients. This suggests the need for ongoing monitoring and potential adjustments in treatment strategies for patients with persistent inflammation.

Conclusion

The findings highlight the importance of understanding residual intrathecal inflammation in RRMS patients treated with NTZ, particularly regarding the implications for long-term disease management and monitoring.

Related Resources & Content

1. Acta Neuropathologica, 2011 -- Understanding the Pathophysiology of Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis Associated with Natalizumab-Induced Progressive Multifocal Leukoencephalopathy
2. Brain, 2022 -- Neuroimaging Insights into Immune Changes in Schizophrenia and the Impact of a Therapeutic Antibody
3. Acta Neuropathologica, 2021 -- Cortical Microglial Phenotypic Alterations Linked to Meningeal Inflammation in Multiple Sclerosis and Their Association with Neurodegeneration
4. Open Forum Infectious Diseases -- Infliximab Treatment Protocol for Severe Tuberculosis of the Central Nervous System: A Case Series Involving 18 Patients
5. NICE, 2026 -- Recommendations | Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
6. New England Journal of Medicine -- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
7. Frontiers -- Residual inflammation in the cerebrospinal fluid after short-and long-term natalizumab treatment in relapsing-remitting multiple sclerosis
8. NICE Guidance on Natalizumab
9. New England Journal of Medicine on Natalizumab Efficacy
10. Frontiers | Residual inflammation in the cerebrospinal fluid after short-and long-term natalizumab treatment in relapsing-remitting multiple sclerosis